Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site
Daniel Stadlbauer(Icahn School of Medicine at Mount Sinai), Florian Krammer(Semmelweis University), Marta Łuksza(Institute for Advanced Study), Juan Manuel Carreño(Icahn School of Medicine at Mount Sinai), George O’Dell(Icahn School of Medicine at Mount Sinai), Ali H. Ellebedy(Washington University in St. Louis), Shirin Strohmeier(Icahn School of Medicine at Mount Sinai), Hongquan Wan(Center for Biologics Evaluation and Research), Hannah L. Turner(Scripps Research Institute), Meagan McMahon(Seqirus (United States)), Harm van Bakel(Icahn School of Medicine at Mount Sinai), Xueyong Zhu(Scripps Research Institute), Andrew B. Ward(Scripps Research Institute), Zain Khalil(Icahn School of Medicine at Mount Sinai), Viviana Simon(Icahn School of Medicine at Mount Sinai), Ian A. Wilson(Raigmore Hospital)
Cited by 26
Related Papers
Influenza
|Nature Reviews Disease Primers|2018|1.5k
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
|Nature|2017|1.2k
Artificial intelligence–enabled rapid diagnosis of patients with COVID-19
|Nature Medicine|2020|1.1k